belantamab mafodotin | International Myeloma Foundation

African-American female researcher in laboratory

Week in Review

March 26

February and March 2026: What's New in Myeloma? 

female scientist doing lab work

Week in Review

October 30

September and October 2025: What's New in Myeloma? 

female scientist doing lab work

Week in Review

August 28

July and August 2025: What's New in Myeloma?  

doctor prescribing medicine

Week in Review

July 31

June and July 2025: What's New in Myeloma?

imwg conferences series, week in review blog, part 2

Week in Review

July 3

Top Takeaways from the 2025 IMWG Conference Series: Making Sense of Treatment (Part 2 of 2)

teamwork

Week in Review

June 26

May and June 2025: What's New in Myeloma? 

Belantamab Mafodotin with VRd in ASCT

February 13

Belantamab Mafodotin with VRd in ASCT-Ineligible Newly Diagnosed Multiple Myeloma: DREAMM-9 Study Findings

early relapse in myeloma, will blenrep return to the US market?

February 6

Belantamab & CAR T-Cell Therapy: Key ASH 2024 Updates on Early Myeloma Relapse

DREAMM-7: BVd vs DVd in R/R Multiple Myeloma

January 14

DREAMM-7: BVd vs DVd in Relapsed Refractory Multiple Myeloma - Phase 3 Survival & Efficacy Update

Dr. Maria V. Mateos at podium

Week in Review

October 15

Blenrep (belantamab mafodotin) May Be Back for Patients with Multiple Myeloma

DREAMM7 Belamaf BVd versus DVd

July 12

DREAMM-7: Belamaf+BVd vs DVd in RRMM, subgroup analyses of phase 3 trial comparing regimens after relapse

What is the current status of belantamab and its potential reapproval?

July 3

What is the current status of belantamab and its potential reapproval?

Subscribe to belantamab mafodotin

Give Where Most Needed